Search research articles
Contact Us
Filters
Showing results (61-70 of 356) with videos related to
Page
of 36
Sort By:
Expert Opinion on Biological Therapy
|
February 27, 2020
Antibody-based therapies for idiopathic pulmonary fibrosis
Giacomo Sgalla, Mariachiara Flore, Matteo Siciliano, et al.
Clinics in Chest Medicine
|
February 28, 2012
Management of idiopathic pulmonary fibrosis
Stefania Cerri, Paolo Spagnolo, Fabrizio Luppi, et al.
Expert Opinion on Investigational Drugs
|
January 24, 2023
BI 1015550: an investigational phosphodiesterase 4B (PDE4B) inhibitor for lung function decline in idiopathic pulmonary fibrosis (IPF)
Giacomo Sgalla, Jacopo Simonetti, Stefania Cortese, et al.
Expert Opinion on Emerging Drugs
|
November 13, 2023
An update on emerging drugs for the treatment of idiopathic pulmonary fibrosis: a look towards 2023 and beyond
Carmelo Sofia, Alessia Comes, Giacomo Sgalla, et al.
Respirology (Carlton, Vic.)
|
May 9, 2019
Contemporary Concise Review 2018: Interstitial lung disease
Pier-Valerio Mari, Mark G Jones, Luca Richeldi
The Lancet. Respiratory Medicine
|
January 15, 2016
What if we made stratified medicine work for patients?
Nicky Britten, Catherine Pope, Susan Halford, et al.
European Journal of Heart Failure
|
August 8, 2018
Treating heart failure with preserved ejection fraction: learning from pulmonary fibrosis
Francesca Graziani, Francesco Varone, Filippo Crea, et al.
Expert Opinion on Investigational Drugs
|
May 26, 2020
Pamrevlumab for the treatment of idiopathic pulmonary fibrosis
Giacomo Sgalla, Claudia Franciosa, Jacopo Simonetti, et al.
Expert Opinion on Investigational Drugs
|
February 1, 2024
Experimental autotaxin inhibitors for the treatment of idiopathic pulmonary fibrosis
Jacopo Simonetti, Marco Ficili, Giacomo Sgalla, et al.
Expert Opinion on Pharmacotherapy
|
December 15, 2021
Advances with pharmacotherapy for the treatment of interstitial lung disease
Alessia Comes, Giacomo Sgalla, Alessandro Perrotta, et al.
Page
of 36
Search research articles
Search
Showing results (61-70 of 356) with videos related to
Sort By:
Page
of 36
Expert Opinion on Biological Therapy
|
February 27, 2020
Antibody-based therapies for idiopathic pulmonary fibrosis
Giacomo Sgalla, Mariachiara Flore, Matteo Siciliano, et al.
Clinics in Chest Medicine
|
February 28, 2012
Management of idiopathic pulmonary fibrosis
Stefania Cerri, Paolo Spagnolo, Fabrizio Luppi, et al.
Expert Opinion on Investigational Drugs
|
January 24, 2023
BI 1015550: an investigational phosphodiesterase 4B (PDE4B) inhibitor for lung function decline in idiopathic pulmonary fibrosis (IPF)
Giacomo Sgalla, Jacopo Simonetti, Stefania Cortese, et al.
Expert Opinion on Emerging Drugs
|
November 13, 2023
An update on emerging drugs for the treatment of idiopathic pulmonary fibrosis: a look towards 2023 and beyond
Carmelo Sofia, Alessia Comes, Giacomo Sgalla, et al.
Respirology (Carlton, Vic.)
|
May 9, 2019
Contemporary Concise Review 2018: Interstitial lung disease
Pier-Valerio Mari, Mark G Jones, Luca Richeldi
The Lancet. Respiratory Medicine
|
January 15, 2016
What if we made stratified medicine work for patients?
Nicky Britten, Catherine Pope, Susan Halford, et al.
European Journal of Heart Failure
|
August 8, 2018
Treating heart failure with preserved ejection fraction: learning from pulmonary fibrosis
Francesca Graziani, Francesco Varone, Filippo Crea, et al.
Expert Opinion on Investigational Drugs
|
May 26, 2020
Pamrevlumab for the treatment of idiopathic pulmonary fibrosis
Giacomo Sgalla, Claudia Franciosa, Jacopo Simonetti, et al.
Expert Opinion on Investigational Drugs
|
February 1, 2024
Experimental autotaxin inhibitors for the treatment of idiopathic pulmonary fibrosis
Jacopo Simonetti, Marco Ficili, Giacomo Sgalla, et al.
Expert Opinion on Pharmacotherapy
|
December 15, 2021
Advances with pharmacotherapy for the treatment of interstitial lung disease
Alessia Comes, Giacomo Sgalla, Alessandro Perrotta, et al.
Page
of 36